386 related articles for article (PubMed ID: 19200304)
1. Romiplostim: a breakthrough treatment for the management of immune thrombocytopenic purpura.
Newland A
Eur J Haematol Suppl; 2009 Mar; (71):20-5. PubMed ID: 19200304
[TBL] [Abstract][Full Text] [Related]
2. Romiplostim in chronic immune thrombocytopenic purpura.
Cersosimo RJ
Clin Ther; 2009 Sep; 31(9):1887-907. PubMed ID: 19843480
[TBL] [Abstract][Full Text] [Related]
3. Treatment options for chronic refractory idiopathic thrombocytopenic purpura in adults: focus on romiplostim and eltrombopag.
Chouhan JD; Herrington JD
Pharmacotherapy; 2010 Jul; 30(7):666-83. PubMed ID: 20575632
[TBL] [Abstract][Full Text] [Related]
4. Long-term use of the thrombopoietin-mimetic romiplostim in children with severe chronic immune thrombocytopenia (ITP).
Bussel JB; Hsieh L; Buchanan GR; Stine K; Kalpatthi R; Gnarra DJ; Ho RH; Nie K; Eisen M
Pediatr Blood Cancer; 2015 Feb; 62(2):208-213. PubMed ID: 25345874
[TBL] [Abstract][Full Text] [Related]
5. The treatment for primary immune thrombocytopenia with romiplostim in adult and paediatric patients: use experience at a Spanish university hospital.
Marquínez-Alonso I; Escudero-Vilaplana V; Pernía S; Beléndez Bieler C; Fernández-Llamazares CM; Sanjurjo-Sáez M
J Clin Pharm Ther; 2014 Aug; 39(4):376-82. PubMed ID: 24702274
[TBL] [Abstract][Full Text] [Related]
6. Romiplostim: a review of its use in immune thrombocytopenia.
Keating GM
Drugs; 2012 Feb; 72(3):415-35. PubMed ID: 22316355
[TBL] [Abstract][Full Text] [Related]
7. Effect of a thrombopoietin receptor agonist on use of intravenous immune globulin in patients with immune thrombocytopenia.
Zeller MP; Heddle NM; Kelton JG; Hamilton K; Wang G; Sholapur N; Carruthers J; Hsia C; Blais N; Toltl L; Hamm C; Pearson MA; Arnold DM
Transfusion; 2016 Jan; 56(1):73-9. PubMed ID: 26400824
[TBL] [Abstract][Full Text] [Related]
8. Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study.
Tarantino MD; Bussel JB; Blanchette VS; Despotovic J; Bennett C; Raj A; Williams B; Beam D; Morales J; Rose MJ; Carpenter N; Nie K; Eisen M
Lancet; 2016 Jul; 388(10039):45-54. PubMed ID: 27103127
[TBL] [Abstract][Full Text] [Related]
9. Plateletpheresis for postsplenectomy rebound thrombocytosis in a patient with chronic immune thrombocytopenic purpura on romiplostim.
Raval JS; Redner RL; Kiss JE
J Clin Apher; 2013 Aug; 28(4):321-4. PubMed ID: 23450778
[TBL] [Abstract][Full Text] [Related]
10. Romiplostim therapy in children with unresponsive chronic immune thrombocytopenia.
Mokhtar GM; Tantawy AA; El Sherif NH
Platelets; 2012; 23(4):264-73. PubMed ID: 22471399
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia.
Cines DB; Wasser J; Rodeghiero F; Chong BH; Steurer M; Provan D; Lyons R; Garcia-Chavez J; Carpenter N; Wang X; Eisen M
Haematologica; 2017 Aug; 102(8):1342-1351. PubMed ID: 28411254
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial.
Kuter DJ; Bussel JB; Lyons RM; Pullarkat V; Gernsheimer TB; Senecal FM; Aledort LM; George JN; Kessler CM; Sanz MA; Liebman HA; Slovick FT; de Wolf JT; Bourgeois E; Guthrie TH; Newland A; Wasser JS; Hamburg SI; Grande C; Lefrère F; Lichtin AE; Tarantino MD; Terebelo HR; Viallard JF; Cuevas FJ; Go RS; Henry DH; Redner RL; Rice L; Schipperus MR; Guo DM; Nichol JL
Lancet; 2008 Feb; 371(9610):395-403. PubMed ID: 18242413
[TBL] [Abstract][Full Text] [Related]
13. Impact of self-administration of romiplostim by patients with chronic immune thrombocytopenia compared with administration by a healthcare provider.
Selleslag D; Bird R; Altomare I; Giagounidis A; Janssens A; Pabinger I; Pullarkat V; Wei H; Kreuzbauer G
Eur J Haematol; 2015 Feb; 94(2):169-76. PubMed ID: 25039799
[TBL] [Abstract][Full Text] [Related]
14. Use of the novel thrombopoietin receptor-agonist romiplostim, in combination with steroids and immunoglobulins for the increase of platelets prior to splenectomy, in refractory immune thrombocytopenia: a case report.
Sivera P; Ruella M; Gueli A; Hu H; Wade M; Tarella C
Blood Coagul Fibrinolysis; 2012 Jun; 23(4):331-4. PubMed ID: 22343685
[TBL] [Abstract][Full Text] [Related]
15. An open-label extension study evaluating the safety and efficacy of romiplostim for up to 3.5 years in thrombocytopenic Japanese patients with immune thrombocytopenic purpura (ITP).
Shirasugi Y; Ando K; Miyazaki K; Tomiyama Y; Iwato K; Okamoto S; Kurokawa M; Kirito K; Hashino S; Ninomiya H; Mori S; Yonemura Y; Usuki K; Wei H; Lizambri R
Int J Hematol; 2012 Jun; 95(6):652-9. PubMed ID: 22532046
[TBL] [Abstract][Full Text] [Related]
16. Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura.
Jamali F; Lemery S; Ayalew K; Robottom S; Robie-Suh K; Rieves D; Pazdur R
Oncology (Williston Park); 2009 Jul; 23(8):704-9. PubMed ID: 19711585
[TBL] [Abstract][Full Text] [Related]
17. The burden of immune thrombocytopenia in adults: evaluation of the thrombopoietin receptor agonist romiplostim.
Deuson R; Danese M; Mathias SD; Schoonen M; Fryzek J
J Med Econ; 2012; 15(5):956-76. PubMed ID: 22533524
[TBL] [Abstract][Full Text] [Related]
18. Platelet aggregation response in immune thrombocytopenia patients treated with romiplostim.
Al-Samkari H; Van Cott EM; Kuter DJ
Ann Hematol; 2019 Mar; 98(3):581-588. PubMed ID: 30446804
[TBL] [Abstract][Full Text] [Related]
19. Romiplostim in children with chronic refractory ITP: randomized placebo controlled study.
Elalfy MS; Abdelmaksoud AA; Eltonbary KY
Ann Hematol; 2011 Nov; 90(11):1341-4. PubMed ID: 21318572
[TBL] [Abstract][Full Text] [Related]
20. Successful treatment of Immune Thrombocytopenic Purpura (ITP) with the thrombopoietin-mimetic romiplostim.
Meletis J; Katsandris A; Raptis SD; Mantzourani M
Med Sci Monit; 2010 Aug; 16(8):CS100-2. PubMed ID: 20671616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
